Boehringer Ingelheim Vetmedica GmbH, Kathrinenhof Research Center, Walchenseestr. 8-12, 83101 Rohrdorf, Germany.
Boehringer Ingelheim Vetmedica GmbH, Kathrinenhof Research Center, Walchenseestr. 8-12, 83101 Rohrdorf, Germany.
Vet Parasitol. 2022 Dec;312:109837. doi: 10.1016/j.vetpar.2022.109837. Epub 2022 Oct 25.
The efficacy of the topical and injection formulations of eprinomectin (0.5 % w/v topical solution, EPRINEX®; 5 % w/v extended-release injection, LONGRANGE®; Boehringer Ingelheim) against larval and adult stages of the rare bovine large intestine nematodes Chabertia ovina and Oesophagostomum venulosum was evaluated in one Good Clinical Practice study compliant to World Association for the Advancement of Veterinary Parasitology and International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products anthelmintic guidelines. Forty nematode naïve induced infected Brown Swiss calves were allocated into five groups of eight completely at random. Inoculation with isolates obtained in Germany was staggered so that the parasites of the two species were, when the treatments were administered, concurrently fourth-stage larval or adult nematodes, respectively. One group served as untreated control, two groups each received eprinomectin 0.5 % w/v topical solution or eprinomectin 5 % w/v extended-release injection per product label. Animals were necropsied at one and the same day (corresponding to six weeks or two weeks after administration of treatments against fourth-stage larval or adult nematodes) for parasite recovery and count. Both C. ovina (range, 39-604) and O. venulosum (range, 3-23) were recovered from all eight controls while among the 32 calves which were administered topical solution or extended-release injection eprinomectin, only a single C. ovina specimen was isolated from one animal which received the injection product when the nematodes were adult. Eprinomectin treatments were > 99.9 % effective against fourth-stage larval or adult C. ovina and O. venulosum nematodes (p 0.001 at α = 0.05). All animals accepted the treatments well. No adverse events or other health problems were observed in the study animals.
在一项符合世界动物卫生组织和国际兽药监管合作组织关于驱虫剂指导原则的良好临床实践研究中，评估了埃普里诺菌素（0.5%w/v 局部溶液，EPRINEX®；5%w/v 缓释注射剂，LONGRANGE®；勃林格殷格翰）的局部和注射制剂对罕见牛大肠线虫 Chabertia ovina 和 Oesophagostomum venulosum 的幼虫和成虫阶段的疗效。40 头线虫初感染诱导感染的瑞士褐牛小牛被完全随机分配到五组，每组 8 头。用在德国获得的分离物进行接种，使两种寄生虫在给予治疗时分别为同时期的第四期幼虫或成虫线虫。一组作为未处理对照，两组分别按产品标签接受埃普里诺菌素 0.5%w/v 局部溶液或埃普里诺菌素 5%w/v 缓释注射剂。动物在同一天（分别对应于给予第四期幼虫或成虫线虫治疗后六周或两周）进行尸检，以回收和计数寄生虫。所有 8 个对照中均回收了 C. ovina（范围 39-604）和 O. venulosum（范围 3-23），而在接受局部溶液或缓释注射埃普里诺菌素治疗的 32 头小牛中，只有一只接受注射产品的动物在成虫时分离出单一的 C. ovina 标本。埃普里诺菌素治疗对第四期幼虫或成虫 C. ovina 和 O. venulosum 线虫的有效性>99.9%（p<0.001，α=0.05）。所有动物均能很好地接受治疗。在研究动物中未观察到不良反应或其他健康问题。
